FDA Issues Form 483 to Zydus Lifesciences
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus. Studies have demonstrated that ZYIL1 is highly potent in human whole blood assay and can suppress inflammation caused by the NLRP3 inflammasome
Zydus Lifesciences on Wednesday said the US health regulator has issued a Form-483 with four observations following the inspection of its Ahmedabad-based SEZ Onco Injectable manufacturing plant.
Zydus launches anti-cancer generic drug olaparib in India
Zydus aims to launch first new drug in US by early 2026
Zydus Lifesciences gets USFDA nod for generic drug to prevent chest pain
India's Zydus Lifesciences beats Q3 profit estimates; approves shares buyback
Zydus Lifesciences launches Rexigo
Zydus launches pill for prostate cancer patients
Zydus gets USFDA nod for generic medication